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AbstrACt
Introduction Thiamine (vitamin B1) deficiency 
remains a concern in Cambodia where women with low 
thiamine intake produce thiamine-poor milk, putting 
their breastfed infants at risk of impaired cognitive 
development and potentially fatal infantile beriberi. 
Thiamine fortification of salt is a potentially low-cost, 
passive means of combating thiamine deficiency; 
however, both the dose of thiamine required to optimise 
milk thiamine concentrations as well as usual salt intake 
of lactating women are unknown.
Methods and analysis In this community-based 
randomised controlled trial, 320 lactating women from 
Kampong Thom, Cambodia will be randomised to one of 
four groups to consume one capsule daily containing 0, 
1.2, 2.4 or 10 mg thiamine as thiamine hydrochloride, 
between 2 and 24 weeks postnatal. The primary objective 
is to estimate the dose where additional maternal intake of 
thiamine no longer meaningfully increases infant thiamine 
diphosphate concentrations 24 weeks postnatally. At 
2, 12 and 24 weeks, we will collect sociodemographic, 
nutrition and health information, a battery of cognitive 
assessments, maternal (2 and 24 weeks) and infant (24 
weeks only) venous blood samples (biomarkers: ThDP 
and transketolase activity) and human milk samples (also 
at 4 weeks; biomarker: milk thiamine concentrations). 
All participants and their families will consume study-
provided salt ad libitum throughout the trial, and we 
will measure salt disappearance each fortnight. Repeat 
weighed salt intakes and urinary sodium concentrations 
will be measured among a subset of 100 participants. 
Parameters of Emax dose–response curves will be 
estimated using non-linear least squares models with both 
‘intention to treat’ and a secondary ‘per-protocol’ (capsule 
compliance ≥80%) analyses.
Ethics and dissemination Ethical approval was 
obtained in Cambodia (National Ethics Committee for 
Health Research 112/250NECHR), Canada (Mount Saint 
Vincent University Research Ethics Board 2017–141) 
and the USA (University of Oregon Institutional Review 
Board 07052018.008). Results will be shared with 
participants’ communities, as well as relevant government 
and scientific stakeholders via presentations, academic 
manuscripts and consultations.
trial registration number NCT03616288.
bACkground
Thiamine (vitamin B1) is an essential 
water-soluble micronutrient required for 
energy metabolism and nerve impulse 
conduction.1 2 Thiamine deficiency was 
recently called the forgotten disease of Asia,3 
strengths and limitations of this study
 ► Human milk is thiamine-responsive; however, this 
is the first study to assess the dose of thiamine 
required to optimise human milk thiamine con-
centrations, vital information required to inform 
fortification programmes (minimise costs and un-
necessary overages).
 ► Previous work has identified delayed cognitive de-
velopment among children with low thiamine intake 
in early life; however, this will be the first study to 
explore cognitive development among infants with 
controlled thiamine exposures in the first 6 months 
postnatal.
 ► We will collect mother’s blood, human milk and in-
fant’s blood at 24 weeks postnatal, enabling a ro-
bust evaluation of associations between maternal 
supplementation and these biomarkers.
 ► The study intervention begins at 2 weeks postnatal, 
so while randomisation should prevent pretreatment 
differences between treatment groups, we will not 
have biochemical thiamine status of the mother 
during pregnancy, nor the infant at birth.
 ► Household salt disappearance measures may over-
estimate or underestimate actual usual salt intake 
as it will not account for wastage, nor salt from food 
consumed outside the home (eg, with relatives, pur-
chased at market), respectively.
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as it remains an understudied public health issue despite 
evidence of suboptimal thiamine intake or status in the 
region,4 including Cambodia.5–11 Thiamine deficiency is 
of particular concern among lactating women because 
mothers with poor dietary thiamine intake and/or status 
produce milk low in thiamine, putting their exclusively 
breastfed infants at a high risk of developing infantile 
beriberi.12 Infantile beriberi presents during the exclu-
sive breastfeeding period and without treatment can 
result in death within hours of clinical presentation.4 13 
In addition, a growing body of evidence from an unfor-
tunate ‘natural experiment’ in which thiamine was erro-
neously omitted from infant formula14 suggests that 
thiamine deficiency not severe enough to cause clinical 
beriberi symptoms can negatively impact cognitive devel-
opment and functioning.15–17 To date, the precise path-
ways and mechanisms remain poorly understood, and 
important questions remain about the timing and levels 
of deficiency, as well as the ability of prophylactic or ther-
apeutic interventions to prevent or remediate the effects 
of suboptimal thiamine status on cognitive outcomes in 
humans.18 
Thiamine is found in pork, whole grains and legumes,1 
and must be consumed routinely due to the relatively 
short half-life and lack of body storage.4 Lactating women 
have an estimated average requirement (EAR) and recom-
mended dietary allowance (RDA) for thiamine of 1.2 and 
1.4 mg/day, respectively.19 For infants aged 0–6 months, 
an adequate intake (AI) of 0.2 mg/day was derived using 
the human milk thiamine concentrations from healthy, 
well-nourished mothers, assuming a daily milk intake of 
780 mL.19
The dietary staple of Cambodia is B-vitamin poor, 
white, polished rice, which accounts for upwards of 60% 
of daily energy intake.20 Given the challenges associated 
with supplementation and changing dietary patterns 
(recently reviewed in Whitfield et al4), fortification, a 
sustainable, cost-effective and passive intervention,21–24 
is a potentially suitable solution for improving maternal 
thiamine intake.23 Thiamine has few technical constraints 
as a fortificant,21 and there is no tolerable upper intake 
level (UL) for thiamine because there have been no 
reports of adverse effects of excess thiamine intake.19 25 26 
We recently demonstrated that maternal consumption 
of thiamine-fortified fish sauce significantly increased 
maternal, human milk, and infant thiamine status8 
However, centrally produced fish sauce may not reach 
the poorest communities who make their own fish sauce, 
and consumption of this condiment is not universal in all 
regions where we find thiamine deficiency.27 28 Conversely, 
salt is a common condiment in most regions of the world, 
and has proven to be a successful global fortification 
vehicle for iodine.29 30
The overall aim of this study is to obtain the information 
necessary to formulate a thiamine-fortified salt for future 
use in Cambodia (ideal thiamine dose, usual salt intake), 
and to explore the impact of various doses of maternal 
thiamine on markers of infant cognitive development.
study outCoMEs And AnAlysIs objECtIvEs
Primary outcome and analysis objective: To estimate 
the dose on the dose–response curve where additional 
maternal intake of thiamine (oral dose) no longer mean-
ingfully increases human milk total thiamine concentra-
tion at 24 weeks postpartum.
secondary outcomes and analysis objectives
1. To estimate the dose on the dose–response curve 
where additional maternal intake of thiamine (oral 
dose) no longer meaningfully increases infant thia-
mine diphosphate concentrations (ThDP) 24 weeks 
postnatally, and assess whether this depends on the 
presence/absence of a genetic haemoglobin disorder.
2. To estimate the dose on the dose–response curve 
where additional maternal intake of thiamine (oral 
dose) no longer meaningfully increases human 
milk total thiamine concentration at 4 and 12 weeks 
postpartum.
3. To estimate the dose on the dose–response curve 
where additional maternal intake of thiamine (oral 
dose) no longer meaningfully increases infant tran-
sketolase activity at 24 weeks postnatally, and assess 
whether this depends on the presence/absence of a 
genetic haemoglobin disorder.
4. To estimate the dose on the dose–response curve 
where additional maternal intake of thiamine (oral 
dose) no longer meaningfully increases maternal 
ThDP at 24 weeks postpartum, and assess whether 
this depends on the presence/absence of a genetic 
haemoglobin disorder.
5. To estimate the dose on the dose–response curve 
where additional maternal intake of thiamine (oral 
dose) no longer meaningfully increases maternal 
transketolase activity at 24 weeks postpartum, and as-
sess whether this depends on the presence/absence 
of a genetic haemoglobin disorder.
6. To test for differences between the four randomised 
groups on human milk total thiamine at 4, 12 and 24 
weeks postpartum.
7. To test for differences between the four randomised 
groups on maternal ThDP at 24 weeks postpartum, 
and assess whether this depends on the presence/ab-
sence of genetic haemoglobin disorder.
8. To test for differences between the four randomised 
groups on maternal transketolase activity at 24 weeks 
postpartum and assess whether this depends on the 
presence/absence of a genetic haemoglobin disorder.
9. To estimate usual household salt intake from mean 
fortnightly salt disappearance (weight lost, in g).
10. To estimate salt intake among a subset of 100 lactat-
ing women, their male partners (if applicable), and 
their children 24–59 months (if applicable) using ob-
served weighed salt intake records.
11. To estimate sodium intake using 24-hour urinary so-
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12. To test for differences between infants in the 0 and 
10 mg randomised groups on Composite Mullen 
and the five subscales of the Mullen at 24 weeks 
postnatally.
13. To test for differences between infants in the 
0 and 10 mg randomised groups on Visual Paired 
Comparison Novelty Score and the attention and 
processing speed subscales at 24 weeks postnatally.
14. To test for differences between infants in the 
0 and 10 mg randomised groups on the Language 
Preference Task Score at 24 weeks postnatally.
15. To test for differences between infants in the 0 and 
10 mg randomised groups on oculomotor scores at 24 
weeks postnatally.
16. To determine the effect of inflammation, as mea-
sured by C-reactive protein (CRP) and α−1-acid-gly-
coprotein (AGP) on maternal ThDP at 2 and 24 
weeks postpartum, and infant ThDP at 24 weeks 
postnatal.
MEthods
study design and setting
This is a double-blind, four-parallel arm randomised 
controlled trial among lactating women and their 
newborn infants. The study timeline and data collection 
schedule can be found in figure 1. The study is commu-
nity-based, with data collection taking place in women’s 
homes in Kampong Thom province in central Cambodia. 
All women live rurally, in villages in the catchment 
areas of the following health centres: Tboung Kapoeur, 
Kampong Svay, Sankor, Chey, Salavisai, Prey Kuy, Prey 
Pros and Srayov.
Eligibility criteria
All women must provide written informed consent to 
participate. Participants must meet the following criteria:
 ► mothers of a newborn;
 ► aged 18–45 years;
 ► most recent pregnancy was normal (ie, no known 
chronic conditions, preeclampsia, gestational 
diabetes, etc), and the singleton infant was born 
without complications (eg, low birth weight (<2.5 kg), 
tongue tie, cleft palate);
 ► intends to exclusively breastfeed for 6 months;
 ► resides in Kampong Thom province, Cambodia, and 
is not planning to move in the next 6 months;
 ► is not currently taking, and has not taken any thia-
mine-containing supplements over the previous 4 
months;
 ► is not currently participating in any nutrition 
programmes beyond normal care;
 ► is willing to consume one capsule daily from 2 weeks 
through 24 weeks postpartum;
 ► is willing for her entire household consume only salt 
provided by the study team; and
 ► is willing for the following biological samples to be 
collected: a maternal venous blood sample and human 
milk sample at 2 weeks postpartum, a human milk 
sample at 4 and 12 weeks postpartum and maternal 
and infant blood samples and a human milk sample 
at 24 weeks postpartum.
recruitment, allocation, randomisation and blinding
A participant flow diagram is shown in figure 2. Partic-
ipants will be recruited through antenatal care visits, as 
well as through consultation with local village chiefs, 
elders and health centre staff. Pregnant women will be 
Figure 1 Study timeline and data collection schedule for Trial of thiamine supplementation in Cambodia. CREDI, Caregiver 
Reported Early Development Instruments; wk, week. 
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advised and provided with a general overview of the 
research study, and then the names and contact informa-
tion of interested women will be shared with the research 
assistants, who follow up after delivery to screen for eligi-
bility, obtain consent and enrol women. Recruitment will 
continue on a rolling basis until 320 women are enrolled.
Women will be randomly assigned to one of the four 
treatment groups as described in table 1. Participants, 
research assistants, study investigators and data analysts 
will be blinded to the randomised groups. The rando-
misation will be stratified by health centre and use 
randomly permuted blocks of size 8 within strata to assign 
participants to one of eight treatment codes in the ratio 
1:1:1:1:1:1:1:1 (two treatment codes per treatment group 
to assist with blinding). A computer-generated randomi-
sation schedule was prepared by the study statisticians 
using  ralloc. ado in Stata (College Station, Texas, USA). 
An independent scientist determined which treatment 
code corresponded to which treatment group. When a 
participant is enrolled in the study, the research assistants 
open an envelope labelled with the study ID that contains 
the study ID and accompanying treatment code that will 
be assigned to that participant.
Figure 2 Participant flow chart for Trial of thiamine supplementation in Cambodia. Double EAR, Double EAR group (2.4 mg 
thiamine as thiamine hydrochloride); EAR, EAR group (1.2 mg thiamine as thiamine hydrochloride); Placebo, negative control 
group (placebo; 0 mg thiamine); Positive Control, Positive Control group (10 mg thiamine as thiamine hydrochloride). 
Table 1 Treatment arms for the Trial of thiamine supplementation in Cambodia
Treatment arm Thiamine dose Rationale
Negative control 0 mg/day Negative control (placebo)
EAR 1.2 mg/day 1xthiamine EAR for lactating women19
Double EAR 2.4 mg/day 2xthiamine EAR for lactating women19
Positive control 10 mg/day Positive control (dose currently given in supplemental form in Myanmar)4
EAR, estimated average requirement.
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Intervention
Women will be asked to consume one capsule daily 
between 2 and 24 weeks postnatal. The intervention is 
opaque capsules containing varying amounts of thiamine 
hydrochloride and cellulose filler, as indicated in table 1. 
All thiamine is delivered as thiamine hydrochloride, 
calculated using a 1.271 correction factor (ratio of molec-
ular weights of thiamine hydrochloride and thiamine). 
Capsules were formulated, compounded and packaged 
as 14 day blister packs at the Quinpool Wellness Centre in 
Halifax, Nova Scotia, Canada.
All capsules were formulated and packed in two 
batches in July and November 2018. Thiamine content 
was assessed by an independent laboratory (USANA, Salt 
Lake City, Utah, USA) before distribution to participants, 
and will continue to be assessed bimonthly for the dura-
tion of the study. Capsules will be deemed acceptable if 
the average thiamine concentration for each code (n=10 
samples per code) falls within ±15% of the values shown 
in table 1.
Compliance
Compliance will be assessed fortnightly: research assistants 
will visit the participant’s home to collect the old blister 
pack and complete a capsule count, and to deliver a new 
blister pack. A woman will be considered compliant if she 
consumes ≥80% capsules over the 22-week intervention.
Participant and public involvement in research
This research is being conducted in collaboration with 
the Cambodian Ministry of Health’s National Maternal 
and Child Nutrition Programme, the Cambodian Ministry 
of Planning’s Sub-Committee for Food Fortification and 
Kampong Thom province’s Provincial Health Depart-
ment and Health Operational District. Participants 
and the public will be involved in the dissemination of 
study results (public village meetings to share findings), 
however were not involved in research question develop-
ment, nor the design of the study or intervention.
dAtA And bIologICAl sAMPlE CollECtIon
Data and biological samples will be collected at enrolment 
(between t=0 to 2 weeks postpartum), at 2, 4, 12 and 24 
weeks postnatal as well as during fortnightly monitoring 
visits (see figure 1).
Chart review
Upon enrolment, a healthcare worker in the Health 
Centre will record data from the dyad’s chart such as 
any interventions/events at birth, maternal age, number 
of antenatal care visits, number of iron-folic acid tablets 
consumed, time and date of birth, sex of infant, and 
infant anthropometrics.
Questionnaires
Using an interviewer-administered questionnaire, we 
will collect demographic and socioeconomic informa-
tion, health information including questions about 
sleep (adapted from31) and postpartum depression,32 
limited dietary intake data (eg, perceptions of salt intake, 
postpartum food taboos33) and infant and young child 
feeding (IYCF) knowledge and behaviours at 2, 12 and 24 
weeks postnatal.
Anthropometry
Anthropometric measures are as follows: infants: length, 
weight and head circumference; mothers: height and 
weight. Initial measurements will be taken in the Health 
Centre at delivery, and all other measurements will be 
collected in participant’s homes (2, 12 and 24 weeks post-
natal) using calibrated instruments and standard proto-
cols as per.34
Fortnightly monitoring
Every 2 weeks, research assistants will visit the participant’s 
home to distribute a new blister pack and assess interven-
tion compliance. They will also administer a short ques-
tionnaire about selling or sharing of salt, IYCF practices 
and the household members eating from the common 
household pot.
salt disappearance
At the initial home visit after randomisation, research 
assistants will check that the household has removed all 
salt from the home, and will distribute table salt in special-
ised study containers. Using calibrated scales (1 g gradua-
tion), research assistants will log the initial weight of the 
salt container(s). Participants will be asked to consume 
only salt provided, and since Cambodian families eat 
from a common pot, they will be instructed for all family 
meals to be prepared using this salt. Salt disappearance 
will continue to be assessed at fortnightly visits.
We will also collect supplemental information in a 
subset of households (n=100) using observed weighed 
intakes and maternal urinary sodium concentrations 
(randomly selected from larger study, with a second day 
repeat on non-consecutive days within 1 week of initial 
visit). The participant (mother), the husband/man in 
household aged 18–50 years and a child between 24–59 
months (husband/man and child will not be applicable 
in all households) will be enrolled in this substudy. 
Research assistants will sit in the participants home from 
dawn through dusk, recording, at the individual level, 
intake for the 1–3 individuals for all table salt and salt-con-
taining condiments (eg, fish and soy sauces) consumed. 
For the mothers only, we will assess 24-hour urinary 
sodium concentrations.25 The mother will discard her 
first urine on awakening, record the time and then collect 
all urine over the next 24 hours into a provided container; 
the collection will end after the woman’s first void the 
following morning. The research assistants will visit her 
home to weigh the full container and then take aliquots 
for testing. The urine sample will be temporarily stored 
at −20°C in Kampong Thom for <2 weeks before being 
transported to the National Institute for Public Health 
Laboratory (NIPHL) in Phnom Penh for urinary sodium 
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analysis on a EasyLtye Na/K/Cl Analyser (Medica, Dussel-
dorf, Germany) and urinary creatinine assessment using 
a Kenza 240TX Analyser (Biolabo Diagnostics, Maizy, 
France). We will model thiamine fortification of salt using 
the University of Iowa’s Intake Monitoring, Assessment 
and Planning Program software (http://www. side. stat. 
iastate. edu/ imapp. php).
venous blood samples
Trained, Khmer-speaking nurses will meet mothers and 
infants at their home or a central village location (health 
centre, or village chief’s home) to collect maternal and 
infant blood samples into EDTA-coated tubes. Maternal 
blood samples (9 mL) will be collected at 2 and 24 weeks 
postnatal; infant samples (5 mL) will be collected only at 
24 weeks postnatal. Time of day and time since last meal 
will be recorded.
human milk samples
Human milk samples will be collected using a battery-pow-
ered single breast pump (Swing Breast pump, Medela) at 
2, 4, 12, and 24 weeks postnatal. One full breast expression 
(single breast) will be collected from the breast women 
self-identify as being more ‘full’ (the breast not most 
recently emptied). Since time of day has little effect on 
milk thiamine concentrations,35 samples can be collected 
at any time of day, however, time of day, time since last 
meal, and breast side will be recorded.
blood and human milk processing
Biological samples will be collected in the village, placed 
on ice, and transported to the field lab in Kampong Thom 
within 5 hours of collection for processing. All samples 
will be stored at −20°C for <2 weeks before being trans-
ported to the NIPHL for storage at −80°C. Samples will be 
batch-shipped on dry ice after the 24 weeks postnatal data 
collection is completed.
blood and human milk analysis
Venous blood samples will undergo analysis for both tran-
sketolase activity and thiamine diphosphate concentra-
tions (ThDP) at the NIHR BRC Nutritional Biomarker 
Laboratory at the University of Cambridge in the United 
Kingdom. At 2 weeks postnatal, maternal whole blood 
ThDP and erythrocyte transketolase activity will be 
measured. At 24 weeks postnatal, maternal ThDP and 
transketolase activity will be measured in both whole 
blood and erythrocytes, and infant samples will be assayed 
for whole blood ThDP and erythrocyte transketolase 
activity. When ThDP is assessed in whole blood, concen-
trations must be normalised to haemoglobin concentra-
tions and/or hematocrit36 measured via a HemoCue 201 
portable hemoglobinometer and capillary hematocrit 
tubes, respectively.
Evidence from the 2014 Cambodian National Micro-
nutrient survey indicates that eThDP is affected by 
the presence/absence of genetic haemoglobin disor-
ders (unpublished data). With this, it is vital to assess 
genetic haemoglobin disorders, as this could influence 
participant’s response to thiamine, it may influence tran-
sketolase, and it could change thiamine dosage require-
ments in other countries. Therefore, at one timepoint 
only (2 weeks postnatal for maternal, and 24 weeks post-
natal for infant samples), samples will undergo haemo-
globin capillary electrophoresis analysis to identify 
structural haemoglobin variants.37 Buffy coat samples will 
be stored in the BioBank in the Department of Applied 
Human Nutrition at Mount Saint Vincent University in 
Halifax, Nova Scotia, Canada, for potential later assess-
ment of genetic haemoglobin disorders.
Biomarkers may be influenced by inflammation, which 
is common in this population.38 39 Plasma samples will be 
sent to Dr. Jurgen Erhardt at the VitMin Lab in Germany 
for analysis of C-reactive protein (CRP) and α−1-acid-gly-
coprotein (AGP) using an immunosorbent assay.40 Note 
that this assay will also measure retinol binding protein 
(RBP), ferritin, and soluble transferrin receptor (sTfR). 
Other plasma samples will be stored in the BioBank for 
potential future use.
The weight of the full human milk expression will be 
recorded, the sample mixed, and 2 mL aliquots obtained 
in amber cryovials. Human milk thiamine concentrations 
will be measured at the USDA/ARS Western Human 
Nutrition Research Center, University of California, 
Davis.41 Additional human milk samples will be stored in 
the BioBank for potential future use.
Cognitive assessments
We will conduct cognitive assessments at 2, 12, and 24 
weeks postnatal; see figure 1 for battery of assessments 
at each timepoint. Assessments include: the Hammer-
smith Infant Neurological Exam, Infant Mullen Scales of 
Early Learning, a Primary Engagement Task, a Secondary 
Engagement Task, the Caregiver Reported Early Devel-
opment Instruments (CREDI), an oculomotor exam, the 
Visual Paired Comparison task, and the Language Prefer-
ence task.
The Hammersmith Infant Neurological Exam is a stan-
dard tool for providing basic information about infants’ 
neurological status through use of gentle touch and gentle 
social interaction in order to examine infants’ sensory 
and motor responses; it has previously shown excellent 
interobserver reliability even among less experienced 
staff.42 The Infant Mullen Scales of Early Learning is an 
individually administered, multi-domain measure of early 
development, with scales measuring development in visual 
reception, fine motor, gross motor, receptive language, 
and expressive language.43 The Primary Engagement Task 
measures individual variation in infant, caregiver, and 
dyad-level developmental change in the ability to engage 
contingently with the partner in direct positive mutual 
engagement interactions. The Secondary Engagement 
Task measures individual variation in caregiver and infant 
ability to engage mutually in relation to an external object. 
The CREDI is a caregiver-reported measure of child devel-
opment that has been shown to have right validity and reli-
ability in low-resource settings.44 An oculomotor exam has 
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been included because oculumotor disturbances are not 
uncommon among thiamine deficient adults presenting 
with Wernicke’s encephalopathy.45 The Visual Paired 
Comparison task probes infants’ recognition memory and 
attention, and has been used to predict subsequent verbal 
IQ in middle childhood,46 47 and produce measures of 
attention predictive of developmental maturity and better 
cognitive function.48 49 The Language Preference Task is 
designed to measure individual variation in infants’ level 
of interest in the kind of language that caregivers typically 
direct toward infants (aka infant-directed talk or ‘moth-
erese’) relative to a) the kind of language that is typically 
directed toward adults (aka adult-directed talk), and b) 
sounds that are matched in complexity but are non-lin-
guistic (non-linguistic analogue). Over a series of trials, 
infants hear these three different kinds of sound samples 
through an audio speaker (infant-directed talk, adult-di-
rected talk, non-linguistic analogue), and the duration 
that they look toward a visual display during each sound 
sample is subsequently measured from the videotaped 
record collected during the session.
Participant remuneration
All participants will receive a mobile phone and mobile 
phone credits. In addition, modest, study-appropriate 
remuneration such as a sarong or laundry soap will be 
provided at biological sample collection points (2, 4, 12, 
and 24 weeks postnatal, and after urine collection).
safety considerations, safety monitoring, and breaking the 
blinding
There is no UL for thiamine,19 25 26 and therefore no 
necessity for a Serious Adverse Events Committee or a 
Data Safety Monitoring Board in the current study. While 
we are confident that there is a very low risk of serious 
adverse events in this study related to the intervention, 
we do expect some infant deaths in our cohort due to 
other causes. Per the 2014 Cambodian Demographic 
and Health Survey rates of neonatal (birth to 1 month) 
and infant (birth to 1 year) mortality,50 we calculated an 
expected mortality rate in our study to lie between 1.67 
and 3.68 infant deaths.
The master ID list will not be unblinded during the 
study unless in the unlikely event of an adverse event in 
the trial. If there is a medical emergency and unblinding 
of a participant is required, our blinding mechanism 
would allow for only one of the two codes per treatment 
arm to be revealed (as each treatment arm will have 
two codes). We would then document and report to the 
funding agency and all ethics committees why any prema-
ture unblinding occurred.
Once data collection and cleaning is complete, the 
database will be locked and unblinded treatment codes 
will be included in the database because a blinded anal-
ysis is not possible for estimating dose response curves.
sample size calculations
To detect a clinically meaningful difference of 40 µg/L in 
human milk total thiamine concentration between any 
two treatment groups with 90% power, assuming an SD of 
43 µg/L (estimated SD of control group in a Cambodian 
thiamine-fortified fish sauce trial51), 48 women are required 
per treatment group, or a total of 192 women. This sample 
size allows for 20% attrition and uses a two-sided alpha of 
0.0083 for each of the six pairwise comparisons between the 
four treatment groups in order to control the familywise 
error rate at the 0.05 level using a Bonferroni adjustment 
for multiple comparisons. Recruitment of 320 participants 
(80 per group) was planned to allow for some uncertainty 
in the assumed values, particularly the SD which may be 
larger than anticipated.
Simulations of 500 dose-response curves for human 
milk total thiamine concentration were conducted to esti-
mate the precision that this sample size would provide for 
addressing the primary study objective (ie, for estimating 
the dose on the dose response curve where additional 
maternal intake of thiamine (oral dose) no longer mean-
ingfully increases human milk total thiamine concentra-
tion at 24 weeks postpartum, defined as the dose required 
to achieve 90% of the average maximum human milk 
total thiamine concentration). Data were simulated based 
on an average minimum and maximum concentration of 
136 µg/L51 and 210 µg/L,19 respectively, with an SD of 
43 µg/L,51 and reaching 50% and 90% of the maximum 
average concentration at dose 1.2 mg/d (EAR group) and 
2.4 mg/d (double EAR group), respectively. Assuming an 
Emax dose–response curve, the precision of the estimated 
dose is ±1.29 mg/d (ie, the 95% CI for the estimated dose 
will be within ±1.29 mg/d of the point estimate).
data and sample management and security
Participants will be given a unique alpha-numeric study 
ID code, not derived from personal identifiers; this code 
will link all data collected from this individual. All data 
will be collected directly on tablets using structured forms 
designed specifically for this study. Data will be reviewed 
daily by the research assistant and field supervisor before 
secure download and integration with the larger database. 
Data management and security procedures, including 
assurance of confidentiality, adhere to the Canadian 
Tri-Council Policy Statement on Ethical Conduct for 
Research Involving Humans (TCPS2 CORE) guidelines, 
and are outlined in full in the protocol at  clinicaltrials. 
gov (NCT03616288).
data analysis plan
A full statistical analysis plan is published in the  clinical-
trials. gov entry (NCT03616288). The primary analyses will 
be performed on an ‘intention to treat’ basis, where all 
participants will be analysed according to their allocated 
treatment group regardless of compliance. A secondary 
‘per-protocol’ analysis will be performed on the subset 
of women who consumed ≥80% capsules over the study 
period. The parameters of the Emax dose–response curves 
will be estimated using non-linear least squares models. 
Separate curves will be fitted for outcomes measured at 4 
weeks, 12 weeks and 24 weeks postnatal. The dose where 
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additional maternal intake of thiamine no longer mean-
ingfully increases milk thiamine concentration, defined 
as the dose that achieves 90% of the maximum concentra-
tion, will be estimated from the fitted curve with SE esti-
mated by bootstrapping for calculating 95% CI.
Comparisons between treatment groups will be 
performed using linear mixed-effects models to account 
for repeated measurements and adjusted for randomis-
ation strata and levels at 2 weeks postnatal. Interaction 
tests will be performed to assess whether treatment effects 
depend on genetic haemoglobin disorder. Missing data 
will be addressed using multiple imputation to create 100 
complete data sets for analysis, with a sensitivity analysis 
performed on the raw (unimputed) data.52
Ethics and dissemination
Approvals were obtained. This study is registered at  clin-
icaltrials. gov ( ClinicalTrials. gov Identifier NCT03616288 
(7 August 2018); Protocol version 2.1 (24 July 2018)).
Updates on the study will be shared at the monthly 
Cambodian Nutrition Working Group meetings, attended 
by researchers and non-governmental organisations 
(NGO) engaging in nutrition research and programming 
in Cambodia. Scaling Up Nutrition and other relevant 
groups will also be updated regularly. Research results 
will be presented at academic nutrition, public health 
and psychology conferences, and in peer-reviewed jour-
nals that offer open access. Data will be made available on 
a public repository after dissemination.
We plan to create various lay outputs from this study that 
can be used by NGO and government agencies working with 
families, or can be accessed directly by families. We will host 
a Dissemination Workshop in Phnom Penh open to rele-
vant stakeholders (NGOs, government, researchers, media, 
clinicians, public health, all sectors) to share the main 
outcomes of the study, and officially ‘launch’ lay resources. 
We will also return to each community in Kampong Thom 
to conduct a village-wide meeting relaying study results.
trIAl stAtus
Participant recruitment began in August 2018, and data 
collection started on 12 September 2018. We estimate 
data collection will be completed by June 2019.
dIsCussIon
Suboptimal maternal thiamine intake and/or status puts 
exclusively breastfed infants at risk of low thiamine status,12 
impaired cognitive development15–17 and infantile beri-
beri, which can be fatal.13 Thiamine fortification of salt is 
a potentially low-cost and sustainable means of combating 
suboptimal thiamine status; however, knowledge gaps must 
be filled before thiamine fortification can proceed.4 There 
are limited data available on the dose of thiamine required 
by lactating women to optimise the thiamine concen-
trations in their milk. Further, usual salt intake among 
lactating women is unknown. Finally, although there is 
emerging evidence that low thiamine intake in early life 
impacts cognitive development, this has yet to be assessed 
in a controlled research environment. This study is posed to 
address these knowledge gaps and provide valuable infor-
mation to inform any potential future thiamine fortifica-
tion efforts in Cambodia or bordering countries.
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